Randomized, double-blind, placebo-controlled trial to evaluate the effects of adjunctive treatment with Aripiprazole on body weight, metabolic parameters, clinical efficacy, and adverse events in people with psychotic disorders on treatment with Clozapine

Trial Profile

Randomized, double-blind, placebo-controlled trial to evaluate the effects of adjunctive treatment with Aripiprazole on body weight, metabolic parameters, clinical efficacy, and adverse events in people with psychotic disorders on treatment with Clozapine

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Aripiprazole (Primary) ; Clozapine
  • Indications Metabolic syndrome; Psychotic disorders; Weight gain
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 13 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top